Anesthesia · OpioidTrial Updateclinicalmid-term

Oliceridine shows potential to reduce PONV in thyroid surgery compared to sufentanil

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 12:32:35 PM

Assessment confidence: 76% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The potential of oliceridine to reduce postoperative nausea and vomiting (PONV) in thyroid surgery could significantly influence opioid management strategies in surgical settings. If validated, this could shift market dynamics and competitive positioning against traditional opioids like sufentanil. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 3 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain (ClinicalTrials.gov), sub-indication match (pain). Successful outcomes for oliceridine could enhance its market share in the surgical analgesic space, impacting revenue streams for companies involved in opioid products.

Competitive Pressure

The most relevant competitive pressure comes from If oliceridine proves effective in reducing PONV, it could position itself as a preferred analgesic in surgical settings, challenging traditional opioids like sufentanil..

Regulatory Outlook

Regulatory risk is concentrated around If oliceridine demonstrates superior efficacy in reducing PONV, it may lead to label expansions and increased scrutiny on opioid alternatives, affecting approval processes..

Key Risks

Elevated medium regulatory exposure for Oliceridine could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful outcomes for oliceridine could enhance its market share in the surgical analgesic space, impacting revenue streams for companies involved in opioid products.
The implications of oliceridine's efficacy on opioid management strategies and potential market positioning.

What Would Change This Assessment

This becomes more urgent if Monitor further results from this trial and any upcoming studies that may confirm oliceridine's benefits in surgical settings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
New Safety Information or Potential Signals of Serious Risks Identified from the FDA Adverse Event Monitoring System (AEMS)
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparison of the Effectiveness of the Simple Puncture Compared to the Incision of an Abscess on the piLOnidal Sinus
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Sub-indication match (pain); Entity match (oliceridine)
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedmedium relevance
Sub-indication match (pain)
FDA document
View source
Warm intranasal saline irrigation reduces intraoperative blood loss during functional endoscopic sinus surgery: a propensity score-matched cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Oliceridine
Sufentanil

Commercial impact

medium

Successful outcomes for oliceridine could enhance its market share in the surgical analgesic space, impacting revenue streams for companies involved in opioid products.

Regulatory impact

medium

If oliceridine demonstrates superior efficacy in reducing PONV, it may lead to label expansions and increased scrutiny on opioid alternatives, affecting approval processes.

What to watch

Monitor further results from this trial and any upcoming studies that may confirm oliceridine's benefits in surgical settings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.